| Ytd | 0.00% | |
| 1y | 0.00% |
| Open | 70.74 | Prev Close | 70.75 | Low | 70.13 | High | 70.78 | Mkt Cap | 7.43B |
| Vol | 0.00 | Avg Vol | 3.50M | EPS | -2.99 | P/E | -23.58 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | 2.52 | Inst. Own | 90.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-25 | 50-d Avg | 53.47 | 200-d Avg | 35.09 | 1yr Est | 57.00 |
MTSR News
Railpen has raised its takeover proposal for IP Group PLC (LSE:IPO), offering shareholders a mix of
Shares in IP Group PLC (LSE:IPO) rose 9% to 53.5p on Monday after the company reported net asset val
Metsera Inc. (NASDAQ: MTSR - Get Free Report) has been given a consensus rating of "Hold" by the eig
Paramount, Comcast, Netflix, Clearlake, Blackstone, and others drive major M&A activity. On the
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its
Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing
Metsera was the target of a bidding war by pharma giants. The company has an innovative obesity drug
On this episode of Stock Movers with Lisa Mateo: - Metsera (MTSR) shares tank in premarket trading a
Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acqui
Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part o
The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven tre
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 1.5% on Monday.
Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal
Shares in Novo Nordisk NOVOb.CO rose in early trade on Monday, after the Wegovy-maker on Saturday dr
13F filings this week will reveal hedge fund and institutional moves, offering insight into smart mo
Bagsværd, Denmark, 8 November 2025 – Novo Nordisk today confirms that it does not intend to make an
Pfizer prevails over rival Novo Nordisk after an unusual bidding war for the weight-loss startup.
Revised transaction values Metsera at up to $86.25 per share Metsera's Board of Directors unanimousl
Pfizer has submitted a sweetened bid for obesity drug developer Metsera , as its fight against rival